Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04440254

Long Duration Holter ECG in Fabry Disease

Natural History of Cardiac Rhythm and Conduction Disorders in Patients With Fabry Disease Evaluated by Long-Term Implantable Holter ECG

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Other Government
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective is to assess the occurrence of cardiac arrhythmias and conduction disorders during a three-year follow-up using implantable Holter ECG monitoring in 40 patients with Fabry disease. The secondary objectives are to analyze the correlations of these anomalies with changes in cardiac MRI and echocardiographic parameters as biological parameters and overall severity of the disease assessed by MSSI.

Detailed description

The main objective of this non-blinded, monocentric non-randomized study is to assess the occurrence of cardiac arrhythmias and conduction disorders (sinus dysfunction, branch block \[BB\], atrioventricular block \[BAV\], sustained \[TVS\] or non-supported \[TVNS\] ventricular tachycardias, atrial fibrillation \[AF\] during a three-year follow-up in 40 patients with Fabry disease (half with left ventricular hypertrophy) using an implantable Holter ECG device (Medtronic Reveal-LINQ™). The secondary objectives are to analyze the correlations (at 1, 2 and 3 years) of these anomalies with the modifications of : * cardiac MRI \[Magnetic Resonance Imaging\] data at inclusion \[M0\] and at 36 months \[M36\] (left ventricular hypertrophy \[HVG\], amplitude of the T1 signal, extent of fibrosis); MRIs will be performed before implantation and after removal of the Holter to avoid the reading artifacts linked to the device. * echocardiographic measurements of the left ventricle (overall longitudinal strain systolic \[SGL\] and ejection fraction \[FE\]) * biological parameters (BNP or NT-proBNP, ultra-sensitive troponin and Lyso-Gb3) * the overall severity of the disease assessed by MSSI (Mainz Severity Score Index), DFG and proteinuria

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTImplantation (subcutaneous) of a marketed miniaturized Holter ECG recording deviceSubcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region

Timeline

Start date
2021-05-05
Primary completion
2029-04-30
Completion
2029-04-30
First posted
2020-06-19
Last updated
2026-02-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04440254. Inclusion in this directory is not an endorsement.